# Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

> **NCT07703514** · PHASE1 · NOT_YET_RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 60 (estimated)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** cH15/3
- **BIOLOGICAL:** cH4/3
- **BIOLOGICAL:** cH5/1N1
- **BIOLOGICAL:** cH8/1N1
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT07703514
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-18
- **Primary completion:** 2027-04-12
- **Final completion:** 2027-04-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07703514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07703514, "Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07703514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*